A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: approaching (757)

Press release: Young patients set to celebrate 'everyday heroes' during fun-filled week

Description
Young patients at Southampton Children's Hospital are set to celebrate their 'everyday heroes' during a fun-filled week of activities from
Url
/AboutTheTrust/Newsandpublications/Latestnews/2018/October-2018/Press-release-Young-patients-set-to-celebrate-'everyday-heroes'-during-fun-filled-week.aspx

Annual ward staffing review January 2025

Description
[5.15] Report to the Trust Board of Directors, 7th January 2025 Title: Ward Staffing Nursing Establishment Review July 2024 – Octobe
Url
/Media/UHS-website-2019/Docs/About-the-Trust/performance/TB-6-monthly-staffing-review-report.pdf

Ipilimumab Ver 1

Description
Chemotherapy Protocol SKIN CANCER IPILIMUMAB Regimen Skin – Ipilimumab Indication Ipilimumab is recommended, within its marketing authorisation, as an option for treating adults with previous
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinIpilimumabVer1.pdf

Procedure for making triclyceride emulsion

Description
NIHR Southampton Biomedical Research Centre The NIHR Southampton Biomedical Research Centre (BRC) has a tight quality assurance system for the writing
Url
/Media/Southampton-Clinical-Research/Procedures/BRCProcedures/Procedure-for-making-triclyceride-emulsion.pdf

Cemiplimab

Description
Chemotherapy Protocol SKIN CANCER Cemiplimab (350mg) Regimen  Skin – Cemiplimab (350mg) Indication  Metastatic or locally advanced cutaneous squamous cell carcinoma in patients who are not
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Cemiplimab.pdf

Endometrial-Dostarlimab

Description
Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlimab is indicated for patients with; - proven histological diagnosis of endometr
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Durvalumab_14day

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC after radical chemoradiotherapy • WHO performan
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

Durvalumab(28day-1500mg)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication • Durvalumab is indicated where; - the patien
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Pembrolizumab2mg/kg

Description
Chemotherapy Protocol LUNG CANCER Pembrolizumab (2mg/kg) Regimen • NSCLC – Pembrolizumab (2mg/kg) Indication • Pembrolizumab is recommended as an option for treating locally advanced or metas
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab2mgkg.pdf

Nivolumab ver 1 (NSCLC)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab This regimen may require funding. Regimen NSCLC – Nivolumab Indication Metastatic squamous non-small cell lung cancer with
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-ver-1.pdf
1 to 10 of 46
Previous 1 2 3 4 5 Next